JP2021527107A - インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療 - Google Patents

インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療 Download PDF

Info

Publication number
JP2021527107A
JP2021527107A JP2020569836A JP2020569836A JP2021527107A JP 2021527107 A JP2021527107 A JP 2021527107A JP 2020569836 A JP2020569836 A JP 2020569836A JP 2020569836 A JP2020569836 A JP 2020569836A JP 2021527107 A JP2021527107 A JP 2021527107A
Authority
JP
Japan
Prior art keywords
chi
inhibitor
treatment
use according
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527107A5 (enExample
Inventor
ブランコ，パトリック
ラザロ，エスティバリズ
ソーベストレ，ファニー
マットゥイッツィ，オーレリアン
Original Assignee
ユニベルシテ ドゥ ボルドー
センター ナショナル デ ラ レシェルシェ サイエンティフィーク
サントル・オスピタリエ・ユニベルシテール・ドゥ・ボルドー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシテ ドゥ ボルドー, センター ナショナル デ ラ レシェルシェ サイエンティフィーク, サントル・オスピタリエ・ユニベルシテール・ドゥ・ボルドー filed Critical ユニベルシテ ドゥ ボルドー
Publication of JP2021527107A publication Critical patent/JP2021527107A/ja
Publication of JP2021527107A5 publication Critical patent/JP2021527107A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
JP2020569836A 2018-06-14 2019-06-13 インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療 Pending JP2021527107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305729 2018-06-14
EP18305729.8 2018-06-14
PCT/EP2019/065617 WO2019238893A1 (en) 2018-06-14 2019-06-13 Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1

Publications (2)

Publication Number Publication Date
JP2021527107A true JP2021527107A (ja) 2021-10-11
JP2021527107A5 JP2021527107A5 (enExample) 2022-06-17

Family

ID=62791692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569836A Pending JP2021527107A (ja) 2018-06-14 2019-06-13 インターロイキン−１の阻害薬を使用した胎盤性慢性組織球性絨毛間腔炎の治療

Country Status (5)

Country Link
US (1) US20210115131A1 (enExample)
EP (1) EP3807313A1 (enExample)
JP (1) JP2021527107A (enExample)
CN (1) CN112236453A (enExample)
WO (1) WO2019238893A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535299A (en) * 2000-02-21 2006-06-30 Applied Research Systems Use of IL-18 inhibitors
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
ES2677944T3 (es) * 2009-11-25 2018-08-07 Hologic Inc. Detección de infección intraamniótica

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. IMMUNOL. (2007) VOL.179,ISSUE 1, P557-565, JPN6023016121, ISSN: 0005158512 *
J. OBSET. GYNAECOL. RES. (2017)VOL.43, NO.9, P.1504-1508, JPN6023016122, ISSN: 0005045223 *

Also Published As

Publication number Publication date
WO2019238893A1 (en) 2019-12-19
CN112236453A (zh) 2021-01-15
EP3807313A1 (en) 2021-04-21
US20210115131A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
Tang et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy
Maybin et al. Inflammatory pathways in endometrial disorders
Shynlova et al. Inhibition of infection‐mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice
Toldo et al. Interleukin‐1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse
Loverre et al. IL-17 expression by tubular epithelial cells in renal transplant recipients with acute antibody-mediated rejection
Morita et al. Biologics for allergic and immunologic diseases
Gui et al. The disturbance of TH17-Treg cell balance in adenomyosis
Strug et al. RBPJ mediates uterine repair in the mouse and is reduced in women with recurrent pregnancy loss
US20180113139A1 (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders
Zheng et al. C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells
Mansilla-Polo et al. Narrative review and update on biologic and small molecule drugs for hidradenitis suppurativa: an entity with a promising future
Yang et al. The Effect of Granulocyte colony-stimulating factor on endometrial receptivity of implantation failure mouse
Han et al. The intervention effect of nicotine on cervical fibroblast-myofibroblast differentiation in lipopolysaccharide-induced preterm birth model through activating the TGF-β1/Smad3 pathway
US20210115131A1 (en) Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
EP3586840B1 (en) Mmp7 inhibitors for use in treating cystitis
Kawase et al. Inflammatory epidermolysis bullosa acquisita effectively treated with minocycline
Schmid et al. Murine pre-eclampsia induced by unspecific activation of the immune system correlates with alterations in the eNOS and AT1 receptor expression in the kidneys and placenta
Introini et al. Expression profiles of antimicrobial peptides in the genital tract of women using progesterone intrauterine devices versus combined oral contraceptives
US20250282859A1 (en) Use of il-36 inhibitors for the treatment of netherton syndrome
JP7862388B2 (ja) Ｂｔｋ阻害剤を用いて全身性エリテマトーデスを治療する方法
Konenkov et al. Anti-inflammatory activity of serum cytokines (IL-4, IL-10, IL-13) and the natural IL-1β receptor antagonist (IL-1Ra) in women with uterine myoma
Feng et al. Relationship between Th1/Th2 balance and medical abortion outcomes in early medical abortion patients
Buffiere-Morgado et al. Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy
Jamee et al. Autoinflammatory disorders
Lepekhova Evaluation of the effectiveness of combined therapy with intravenous immunoglobulin and plasmapheresis in patients with steroid-resistant form of pemphigus based on the cytokine and chemokine profiles assessment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230926